JP2016508135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508135A5 JP2016508135A5 JP2015549758A JP2015549758A JP2016508135A5 JP 2016508135 A5 JP2016508135 A5 JP 2016508135A5 JP 2015549758 A JP2015549758 A JP 2015549758A JP 2015549758 A JP2015549758 A JP 2015549758A JP 2016508135 A5 JP2016508135 A5 JP 2016508135A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- heterocyclyl
- carbocyclyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 95
- 125000000623 heterocyclic group Chemical group 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 36
- 229910052799 carbon Inorganic materials 0.000 claims 35
- 125000004452 carbocyclyl group Chemical group 0.000 claims 28
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 3
- -1 CN Inorganic materials 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 102000008122 Casein Kinase I Human genes 0.000 claims 2
- 108010049812 Casein Kinase I Proteins 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 0 CCc([n](*)nc1-c2ccc(C)cc2)c1-c(c(*)c1*)n[n]2c1nc(NC(*)=O)c2* Chemical compound CCc([n](*)nc1-c2ccc(C)cc2)c1-c(c(*)c1*)n[n]2c1nc(NC(*)=O)c2* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740552P | 2012-12-21 | 2012-12-21 | |
| US61/740,552 | 2012-12-21 | ||
| PCT/US2013/076806 WO2014100540A1 (en) | 2012-12-21 | 2013-12-20 | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508135A JP2016508135A (ja) | 2016-03-17 |
| JP2016508135A5 true JP2016508135A5 (enExample) | 2017-01-12 |
| JP6283688B2 JP6283688B2 (ja) | 2018-02-21 |
Family
ID=49943574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549758A Expired - Fee Related JP6283688B2 (ja) | 2012-12-21 | 2013-12-20 | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9475817B2 (enExample) |
| EP (1) | EP2935272B1 (enExample) |
| JP (1) | JP6283688B2 (enExample) |
| CN (1) | CN104837844B (enExample) |
| WO (1) | WO2014100540A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2935271B1 (en) | 2012-12-21 | 2017-10-25 | Bristol-Myers Squibb Company | Novel substituted imidazoles as casein kinase 1 / inhibitors |
| EP3157925B1 (en) | 2014-06-19 | 2019-12-18 | Bristol-Myers Squibb Company | Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors |
| EP4591936A3 (en) | 2015-03-23 | 2025-10-15 | Tianli Biotech Pty Ltd | Treatment of respiratory diseases |
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| WO2020093098A1 (en) | 2018-11-07 | 2020-05-14 | The University Of Melbourne | Novel compounds for the treatment of respiratory diseases |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3139285A1 (en) * | 2019-06-27 | 2020-12-30 | Hangzhou Healzen Therapeutics Co., Ltd. | Casein kinase 1e inhibitor, pharmaceutical composition and application thereof |
| CN112451529A (zh) * | 2020-12-18 | 2021-03-09 | 忻佑康医药科技(南京)有限公司 | Kb-NB 142-70的药物新用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JPWO2008016131A1 (ja) | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| FR2918986B1 (fr) * | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| CN101981033B (zh) * | 2008-02-06 | 2015-02-04 | 百时美施贵宝公司 | 用作激酶抑制剂的取代的咪唑并哒嗪化合物 |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) * | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| PL3181133T3 (pl) * | 2010-12-20 | 2019-12-31 | Pfizer Inc. | Nowe skondensowane związki pirydyny jako inhibitory kinazy kazeiny |
| EP2935271B1 (en) | 2012-12-21 | 2017-10-25 | Bristol-Myers Squibb Company | Novel substituted imidazoles as casein kinase 1 / inhibitors |
-
2013
- 2013-12-20 JP JP2015549758A patent/JP6283688B2/ja not_active Expired - Fee Related
- 2013-12-20 EP EP13818939.4A patent/EP2935272B1/en not_active Not-in-force
- 2013-12-20 CN CN201380066075.3A patent/CN104837844B/zh not_active Expired - Fee Related
- 2013-12-20 WO PCT/US2013/076806 patent/WO2014100540A1/en not_active Ceased
- 2013-12-20 US US14/653,878 patent/US9475817B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507502A5 (enExample) | ||
| JP2016508135A5 (enExample) | ||
| JP2017518344A5 (enExample) | ||
| ES2925564T3 (es) | Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos | |
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| JP2016537366A5 (enExample) | ||
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2016537369A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| JP2016516043A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| CN111918652A (zh) | 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂 | |
| JP2011519956A5 (ja) | キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬 | |
| JP2015504076A5 (enExample) |